|
|
|||||||
Malignant Lymphomas |
From the Laboratory of Immunotherapy, Clinic I of Internal Medicine, University Hospital Cologne, Cologne, Germany, Center for Molecular Medicine, University Hospital Cologne, Cologne, Germany
Correspondence: Bastian von Tresckow, M.D., University Hospital Cologne, Laboratory of Immunotherapy, Department of Internal Medicine I, LFI-Eb.4, room 703, Kerpener Str. 62, 50924 Cologne, Germany. E-mail: bastian.von-tresckow{at}ukkoeln.de
Statins are used to treat hypercholesterolemia and seem to have a preventive effect against cancer through pleiotropic effects including prenylation-inhibition. So far nothing is known about the activity of statins or more specific prenylation-inhibitors in Hodgkins lymphoma (HL). We, therefore, evaluated the anti-HL activity of simvastatin and specific prenylation-inhibitors. Two µM Simvastatin induced caspase-related apoptosis via depletion of prenylation-substrates in several HL-cell lines. Furthermore, it effectively impaired tumor growth in a mouse model for HL. Since the prenylation-inhibitors FTI-277 and GGTI-298 were also effective against HL-cells, we conclude that statins and specific prenylation-inhibitors should be evaluated in HL patients.
Key words: lymphoma, apoptosis, growth control, statins.
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |